Prothena FY2026 Earnings Forecast Increased by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA) – Research analysts at HC Wainwright raised their FY2026 EPS estimates for Prothena in a report issued on Friday, November 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of ($0.44) per share for the year, up from their previous estimate of ($0.47). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Prothena’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $0.96 EPS, FY2029 earnings at ($1.48) EPS and FY2030 earnings at $2.26 EPS.

Several other brokerages have also commented on PRTA. Weiss Ratings lowered Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Wall Street Zen lowered Prothena from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, UBS Group reaffirmed a “buy” rating on shares of Prothena in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Prothena presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Prothena Stock Up 10.0%

Shares of PRTA stock opened at $8.77 on Tuesday. The business has a 50-day moving average price of $8.64 and a two-hundred day moving average price of $9.19. Prothena has a 12-month low of $7.73 and a 12-month high of $11.80. The firm has a market cap of $459.11 million, a P/E ratio of -18.27, a price-to-earnings-growth ratio of 2.96 and a beta of -0.20.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). Prothena had a negative net margin of 80.68% and a negative return on equity of 16.45%. The firm had revenue of $0.62 million during the quarter, compared to the consensus estimate of $9.58 million.

Institutional Investors Weigh In On Prothena

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new stake in shares of Prothena during the third quarter worth about $239,000. Chicago Partners Investment Group LLC grew its stake in shares of Prothena by 59.8% in the third quarter. Chicago Partners Investment Group LLC now owns 25,779 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 9,650 shares during the last quarter. Pinnacle Associates Ltd. increased its holdings in Prothena by 6.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 61,507 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 3,589 shares during the period. Versant Capital Management Inc increased its holdings in Prothena by 179.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,704 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 3,660 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in Prothena during the 2nd quarter valued at about $404,000. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Prothena

In related news, major shareholder William P. Scully acquired 50,000 shares of Prothena stock in a transaction dated Friday, October 23rd. The shares were purchased at an average cost of $8.07 per share, with a total value of $403,500.00. Following the completion of the purchase, the insider owned 1,187,000 shares of the company’s stock, valued at $9,579,090. This represents a 4.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 1,017,500 shares of company stock worth $8,654,850 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

More Prothena News

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $30 target, well above the share price cited in the background. It also modestly improved its FY2026 EPS forecast, narrowing the projected loss to $0.44 from $0.47 per share. Prothena analyst coverage
• Negative Sentiment: The analyst lowered forecasts for FY2027 EPS to a loss of $1.51 from $1.28, FY2028 to earnings of $0.96 from $1.10, FY2029 to a loss of $1.48 from $1.25, and FY2030 to earnings of $2.26 from $2.37. The Q4 2026 loss forecast also widened to $0.44 per share from $0.38. These revisions temper the bullish rating and target. Prothena analyst coverage

About Prothena

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.